2024 American Association of Cancer Research Annual Meeting (AACR 2024) will be held from April 5-10, 2024, in San Diego, United States. As the focal point of the cancer research community globally, countless latest scientific and medical studies in tumor field are first published here every year. In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized. The abstracts are available on AACR’s official website.

Abstracts：

GT0486（mTORC1/2）

Title: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors

Session Category: Clinical Research

Session Title: Targeting Kinase and ERK Pathways

Session Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM UTC

Location: Poster Section 46

Poster Board Number: 26

Nivo813（PD-1/ALK-1）

Title: High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors

Session Category: Immunology

Session Title: Single Target and Bispecific Antibodies

Session Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM UTC

Location: Poster Section 6

Poster Board Number: 26

GT19870（GSPT1/Myc Molecular Glue）

Title: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors

Session Category: Experimental and Molecular Therapeutics

Session Title: Molecular Glues

Session Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM UTC

Location: Poster Section 27

Poster Board Number: 4

Youzhi Tong, the founder, chairman, and CEO of Kintor, said, “Developing anti-cancer drugs is a challenging but profoundly meaningful task. We are pleased that our studies have demonstrated excellent R&D potential. Our GT0486, which can combo with BTK inhibitor, may overcome drug resistance issue; our Nivo813, which can bind potency to cell surface PD-1 and ALK-1 simultaneously, showing excellent anti-tumor effects both in vivo and in vitro; our GT19870, targeting the extremely difficult target c-Myc, has been showcased at international conferences multiple times. We will continue to delve into our research, hoping more patients can be benefit from R&D and technological innovation, and take the social responsibility as an innovative biotech company.”